December 1, 2011

The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

PUBLICATION: 
European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742–2749.

AUTHORS: 
Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso

SUMMARY: 
The logistically complex MINDACT trial is feasible in a multinational setting. The proportion of discordant patients, the potential reduction in CT by using the genomic signature and compliance to treatment assignment are in accordance with the trial hypotheses.

Read more: Rutgers et al_2011_European Journal of Cancer_The EORTC 10041…